Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Will Advanced Technology Simulations Lead To More And Better Drugs? Start-Up Schrodinger Says It Can
Schrodinger LLC is a leading player in the emerging high-stakes field of computational chemical simulation software to boost the quality and productivity of drug discovery and lead generation. Its business model relies heavily on validating theoretical concepts of science and engineering in real-world settings through partnerships with a blue-chip list of pharma and biotech companies.
EY executive survey yields insights into how digital technology is helping drive biopharma deal strategy and aiding companies to meet competitive challenges.
Winners Are Beginning To Emerge In Digital Health – But Without Planning Medtechs Risk Missing The Boat
The leading medtechs are starting to develop models for providers that show how to implement successful digital strategies, a trend that is serving to put pressure on companies that are yet to make a commitment, says ZS Associates' Pete Masloski.
While digital health applications represent a major opportunity for biopharma, acting on the premise – and realizing its promise – depends on quantum-level shifts in organizational design and cultural resilience to disruptive change. In an In Vivo interview, Omnicom Health Group’s SVP for Data Solutions Christina Kim says industry progress toward a digitized future varies, but the necessity to act is clear.
A once-in-a-generation opportunity has opened to digitally redesign a core part of the biopharma business. Capturing the opportunity requires vision and leadership; it’s not about the technology.
For an industry whose central structural dilemma is the slow pace of progress from bench to bedside, GE stands out as an exemplar of success – its performance on speed-to-market product launch has been studied extensively by big pharma strategists. GE Healthcare’s Tom McGuinness tells In Vivo how his division is doubling down on this record, using software and data analytics to help biopharma become more efficient in moving products to patients.
The House Energy and Commerce Committee is asking stakeholders to help prevent cyberattacks on medical devices and systems, citing recent attacks. One key issue cited by the committee: simply asking companies to update legacy devices or switching out those devices for newer ones is unfeasible.
After Abbott recently settled a case against short-seller Muddy Waters, the company has put out a second cybersecurity patch for certain St. Jude radio-frequency enabled cardiac devices to stop potential hackers from harming patients.
In a new "action plan," FDA is stitching together a plethora of ongoing and proposed initiatives to help spur product safety and quality efforts through increased regulatory authority and more incentives for device-makers.
As the threat of cybersecurity vulnerabilities in medtech has grown, so has interest in tackling the problem from both industry and regulators. In an effort to assist in developing a manual to help companies manage threats, the public-private Medical Device Innovation Consortium is taking research bids.
Philips and Digital China Health, the largest provider of cloud-based healthcare services in China, have launched the Shinefly teleradiology application and services platform to help Chinese health-care providers manage their radiology workload and information output.
A new cybersecurity threat report looking across industries suggests the fear of medical devices being hacked has so far not materialized. Unlike other industries, health care is ripe with data breaches that are caused by internal actors rather than malicious hackers.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.